title: An extract of green tea, epigallocatechin-3-gallate, reduces periapical lesions by inhibiting cysteine-rich 61 expression in osteoblasts.
abstract: Recent investigations indicate that epigallocatechin-3-gallate (EGCG), the major polyphenol of green tea, has anti-inflammatory properties. This study assessed the effect of EGCG on oncostatin M (OSM)-induced synthesis of cysteine-rich 61 (Cyr61), a potential osteolytic mediator, in MG-63 human osteoblastic cells. The therapeutic effect of EGCG in apical periodontitis in rats was also examined. Western blot analysis showed that OSM stimulated Cyr61 synthesis in MG-63 in a time-dependent manner, whereas EGCG readily attenuated this effect. On the other hand, Cyr61 treatment of MG-63 cells induced the release of CCL2, a chemokine responsible for macrophage chemotaxis. In a rat model of induced apical periodontitis, radiography and histopathology revealed that administration of EGCG markedly diminished the severity of periapical lesions. The numbers of Cyr61-synthesizing osteoblasts and infiltrating macrophages were also decreased. Thus, EGCG suppresses the progression of apical periodontitis, possibly by diminishing Cyr61 expression in osteoblasts and, subsequently, macrophage chemotaxis into the lesions.
authors.affiliation: School of Dentistry, College of Medicine, National Taiwan University, Taipei, Taiwan.
authors.forename: Yuan-Ling
authors.initials: YL
authors.lastname: Lee
authors.forename: Chi-Yuan
authors.initials: CY
authors.lastname: Hong
authors.forename: Sang-Heng
authors.initials: SH
authors.lastname: Kok
authors.forename: Kuo-Liang
authors.initials: KL
authors.lastname: Hou
authors.forename: Yi-Ting
authors.initials: YT
authors.lastname: Lin
authors.forename: Mu-Hsiung
authors.initials: MH
authors.lastname: Chen
authors.forename: Chih-Chiang
authors.initials: CC
authors.lastname: Wang
authors.forename: Sze-Kwan
authors.initials: SK
authors.lastname: Lin
mesh_terms: D016301:Alveolar Bone Loss / Q000188:drug therapy; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use*; D002392:Catechin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D045744:Cell Line, Tumor; D018932:Chemokine CCL2 / Q000096:biosynthesis; D002634:Chemotaxis, Leukocyte / Q000187:drug effects; D055515:Cysteine-Rich Protein 61 / Q000037:antagonists & inhibitors*; D004195:Disease Models, Animal; D006801:Humans; D053683:Oncostatin M / Q000378:metabolism; D010006:Osteoblasts / Q000187:drug effects* / Q000378:metabolism; D010485:Periapical Periodontitis / Q000188:drug therapy*; D010936:Plant Extracts / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D013662:Tea / Q000737:chemistry
chemical_list: D000975:Antioxidants; D018932:Chemokine CCL2; D055515:Cysteine-Rich Protein 61; D010936:Plant Extracts; D013662:Tea; D053683:Oncostatin M; D002392:Catechin; C045651:epigallocatechin gallate